2-(4-methoxy-phenyl)-5,6,7,8-tetrahydroimidazo[2,1-b]benzothiazole | 60477-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-methoxy-phenyl)-5,6,7,8-tetrahydroimidazo[2,1-b]benzothiazole
• 英文别名: 2-(4-Methoxyphenyl)-5,6,7,8-tetrahydroimidazo[2,1-b][1,3]benzothiazole
• CAS: 60477-35-2
• 化学式: C₁₆H₁₆N₂OS
• 分子量: 284.382
• InChiKey: RQGHLASMYPXWEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  环己酮 在 碘 作用下， 以 乙醇 、 水 为溶剂， 反应 6.33h， 生成 2-(4-methoxy-phenyl)-5,6,7,8-tetrahydroimidazo[2,1-b]benzothiazole
  参考文献：
  名称：

  이미다조티아졸 유도체 또는 이의 약학적으로 허용 가능한 염 및 이의 의약적 용도

  摘要：

  本发明涉及一种抑制NF-κB活性的新型咪唑硫唑化合物及其医学用途，更详细地说，根据本发明，新型咪唑硫唑（Imidazothiazole）衍生物通过抑制炎症环境中核因子κB（NF-κB）的基因表达和活性，抑制了炎症细胞因子前体物质IL-6和TNF-α的产生，并表现出抑制NO生成的效果。因此，含有本发明的新型咪唑硫唑（Imidazothiazole）衍生物作为有效成分的组合物可用作治疗皮肤疾病、炎症性疾病或感染性疾病的药物组合物。

  公开号：

  KR20170023387A

文献信息

• Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
  申请人：Phio Pharmaceuticals Corp.

  公开号：US10808247B2

  公开（公告）日：2020-10-20

  In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-κB p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.

  在一个方面，本发明公开了治疗神经退行性疾病的方法，包括向有需要的受试者施用治疗有效量的核酸分子和治疗有效量的小分子，该小分子可激活NF-κB p65并增加锰超氧化物歧化酶（MnSOD/SOD2）的表达和/或相关蛋白或酶的表达。
• Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
  申请人：Southern Research Institute

  公开号：US10953017B2

  公开（公告）日：2021-03-23

  Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.

  本文描述了通过服用某些杂环化合物和芳香族化合物来增强记忆和/或学习能力并防止神经变性的方法。这些方法特别适用于治疗神经退行性疾病患者，如（但不限于）阿尔茨海默氏症、帕金森氏症、卢盖里氏症（ALS）或记忆或学习障碍。此外，还提供了一种基于神经元人体细胞的检测方法，利用荧光素酶报告物评估 NF-kB 基因的上调，从而筛选出在增强记忆或学习能力的方法中有用的化合物。
• KRASOVSKIJ A. N.; GRIN N. P.; KOCHERGIN P. M.; KUBRAK L. N., FARMATSIYA. RESP. MEZHVED. SB., 1975, VYP. 2, 26-28
  作者：KRASOVSKIJ A. N.、 GRIN N. P.、 KOCHERGIN P. M.、 KUBRAK L. N.

  DOI：——

  日期：——
• TREATMENT OF NEURODEGENERATIVE DISEASES, CAUSATION OF MEMORY ENHANCEMENT, AND ASSAY FOR SCREENING COMPOUNDS FOR SUCH
  申请人：Grimaldi Maurizio

  公开号：US20120245166A1

  公开（公告）日：2012-09-27

  Methods for enhancing memory and/or learning and prevent neurodegeneration by administration of certain heterocyclic and aromatic compounds are described. The methods are particularly useful for treating patients suffering from a neurodegenerative disease such as (without limitation) Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease or memory or learning impairment. A neuronal human cell-based assay that assess NF-kB gene up-regulation using a luciferase reporter is also provided that screens for compounds useful in methods for enhancing memory or learning.
• METHODS FOR TREATING NEUROLOGICAL DISORDERS USING A SYNERGISTIC SMALL MOLECULE AND NUCLEIC ACIDS THERAPEUTIC APPROACH
  申请人：Rxi Pharmaceuticals Corporation

  公开号：US20180195066A1

  公开（公告）日：2018-07-12

  In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective amount of a small molecule that activates NF-κB p65 and increases expression of manganese superoxide dismutase (MnSOD/SOD2) and/or expression of a related protein or enzyme.